References
Alphs, L. D., and C. A. Bossie. 2016. ASPECT-R—A Tool to Rate the Pragmatic and Explanatory Characteristics of a Clinical Trial Design. Innovations in Clinical Neuroscience 13(1-2):15.
Alphs, L., C. Benson, K. Cheshire-Kinney, J. P. Lindenmayer, L. Mao, S. C. Rodriguez, and H. L. Starr. 2015. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: A randomized, open-label, review board-blinded 15-month study. Journal of Clinical Psychiatry 76(5):554-561.
Avalos, L. A., H. Chen, and D. K. Li. 2015. Antidepressant medication use, depression, and the risk of preeclampsia. CNS Spectrums 20(1):39-47.
Bai, Y., H. Deng, A. Shantsila, and G. Y. Lip. 2017. Rivaroxaban versus Dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: Systematic review and meta-analysis. Stroke 48(4):970-976.
Berger, M. L., H. Sox, R. J. Willke, D. L. Brixner, H. G. Eichler, W. Goettsch, D. Madigan, A. Makady, S. Schneeweiss, R. Tarricone, S. V. Wang, J. Watkins, and C. D. Mullins. 2017. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the Joint ISPOR_ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value in Health 20(8):1003-1008.
Chrischilles, E. A., J. J. Gagne, B. Fireman, J. Nelson, S. Toh, A. Shoaibi, M. E. Reichman, S. Wang, M. Nguyen, R. Zhang, R. Izem, M. R. Goulding, M. R. Southworth, D. J. Graham, C. Fuller, H. Katcoff, T. Woodworth, C. Rogers, R. Saliga, N. D. Lin, C. N. McMahill-Walraven, V. P. Nair, K. Haynes, and R. M. Carnahan. 2018. Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. Pharmacoepidemiology and Drug Safety 27(3):263-271.
Connolly, S. J., M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. A. Reilly, E. Themeles, J. Varrone, and S. Wang. 2009. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 361(12):1139-1151.
Daniel, G. W., M. Menis, G. Sridhar, D. Scott, A. E. Wallace, M. V. Ovanesov, B. Golding, S. A. Anderson, J. Epstein, D. Martin, and R. Ball. 2012. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion 52(10):2113-2121.
DiMasi, J. A., H. G. Grabowski, and R. W. Hansen. 2016. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics 47:20-33.
Evidation and Novartis. 2018. Real-world use of wearable devices in a large multiple sclerosis cohort. Poster presentation at the American Academy of Neurology Annual Meeting, Los Angeles, CA.
Fergusson, D. A., P. C. Hébert, C. D. Mazer, S. Fremes, C. MacAdams, J. M. Murkin, K. Teoh, P. C. Duke, R. Arellano, M. A. Blajchman, and J. S. Bussières. 2008. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. New England Journal of Medicine 358(22):2319-2331.
Fralick, M., S. Schneeweiss, and E. Patorno. 2017. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. New England Journal of Medicine 376(23):2300-2302.
Franklin, J. M., and S. Schneeweiss. 2017. When and how can real world data analyses substitute for randomized controlled trials? Clinical Pharmacology & Therapeutics 102(6):924-933.
Galson, S., and G. Simon. 2016. Real-World Evidence to Guide the Approval and Use of New Treatments. NAM Perspectives. Discussion Paper, National Academy of Medicine, Washington, DC. doi: 10.31478/201610b.
Gambhir, S. S., T. J. Ge, O. Vermesh, and R. Spittler. 2018. Toward achieving precision health. Science Translational Medicine 10(430):eaao3612.
Giles, J. T., N. Sattar, S. E. Gabriel, P. M. Ridker, S. Gay, C. Warne, D. Musselman, L. Brockwell, E. Shittu, M. Klearman, and T. Fleming. 2016. Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: Results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial. Arthritis & Rheumatology 68(Suppl 10).
Gill, J., P. Kanavos, B. Avouac, R. Duncombe, J. Hutton, K. Jahnz-Różyk, W. Schramm, F. Spandonaro, and M. Thomas. 2016. The use of real world evidence in the European context: An analysis of key expert opinion. http://www.lse.ac.uk/business-and-consultancy/consulting/assets/documents/the-use-of-real-world-evidence-in-the-european-context.pdf (accessed December 21, 2018).
Giugliano, R. P., C. T. Ruff, E. Braunwald, S. A. Murphy, S. D. Wiviott, J. L. Halperin, A. L. Waldo, M. D. Ezekowitz, J. I. Weitz, J. Špinar, and W. Ruzyllo. 2013. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 369(22):2093-2104.
Go, A. S., E. M. Hylek, L. H. Borowsky, K. A. Phillips, J. V. Selby, and D. E. Singer. 1999. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Annals of Internal Medicine 131(12):927-934.
Goettsch, W., and A. Makady. 2015. Glossary of definitions of common terms. IMI GetReal. https://www.imi-getreal.eu/Portals/1/Documents/01%20deliverables/D1.3%20-%20Revised%20GetReal%20glossary%20-%20FINAL%20updated%20version_25Oct16_webversion.pdf (accessed March 27, 2019).
Gökbuget, N., M. Kelsh, V. Chia, A. Advani, R. Bassan, H. Dombret, M. Doubek, A. K. Fielding, S. Giebel, V. Haddad, D. Hoelzer, C. Holland, N. Ifrah, A. Katz, T. Maniar, G. Martinelli, M. Morgades, S. O’Brien, J. M. Ribera, J. M. Rowe, A. Stein, M. Topp, M. Wadleigh, and H. Kantarjian. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer Journal 6:e473.
Granger, C. B., J. H. Alexander, J. J. McMurray, R. D. Lopes, E. M. Hylek, M. Hanna, H. R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, and M.C. Bahit. 2011. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 365(11):981-992.
Greene, S. M., R. J. Reid, and E. B. Larson. 2012. Implementing the learning health system: From concept to action. Annals of Internal Medicine 157(3):207-210.
Huang, G., X. Sun, D. Liu, Y. Zhang, B. Zhang, G. Xiao, X. Li, X. Gao, C. Hu, M. Wang, H. Ren, and S. Qin. 2018. The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: A meta-analysis. Oncotarget 9(3):4239-4248.
Izurieta, H. S., M. Wernecke, J. Kelman, S. Wong, R. Forshee, D. Pratt, Y. Lu, Q. Sun, C. Jankosky, P. Krause, and C. Worrall. 2017. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older. Clinical Infectious Diseases 64(6):785-793.
Kim, S. C., D. H. Solomon, J. R. Rogers, S. Gale, M. Klearman, K. Sarsour, and S. Schneeweiss. 2017. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: A multi-database cohort study. Arthritis & Rheumatology 69(6):1154-1164.
Kimmelman, J., and A. J. London. 2015. The structure of clinical translation. Hastings Center Report 45(2):27-39.
London, A. J. 2018. Learning health systems, clinical equipoise and the ethics of response adaptive randomization. Journal of Medical Ethics 44:409-415.
Madjid, M., C. C. Miller, V. V. Zarubaev, I. G. Marinich, O. I. Kiselev, Y. V. Lobzin, A. E. Filippov, and S. W. Casscells III. 2007. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: Results from 8 years of autopsies in 34,892 subjects. European Heart Journal 28(10):1205-1210.
Moseley, J. B., K. O’Malley, N. J. Petersen, T. J. Menke, B. A. Brody, D. H. Kuykendall, J. C. Hollingsworth, C. M. Ashton, and N. P. Wray. 2002. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. New England Journal of Medicine 347(2):81-88.
Neal, B., V. Perkovic, K. W. Mahaffey, D. De Zeeuw, G. Fulcher, N. Erondu, W. Shaw, G. Law, M. Desai, and D. R. Matthews. 2017. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine 377(7):644-657.
Palmsten, K., K. F. Huybrechts, K. B. Michels, P. L. Williams, H. Mogun, S. Setoguchi, and S. Hernández-Díaz. 2013. Antidepressant use and risk for preeclampsia. Epidemiology (Cambridge, Mass.) 24(5):682.
Patel, M. R., K. W. Mahaffey, J. Garg, G. Pan, D. E. Singer, W. Hacke, B. Breithardt, J. L. Halperin, G. J. Hankey, J. P. Piccini, R. C. Becker, C. C. Nessel, J. F. Paolini, S. D. Berkowitz, K. A. Fox, and R. M. Califf, for the ROCKET AF Investigators. 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine 365(10):883-891.
Patorno, E., A. B. Goldfine, S. Schneeweiss, B. M. Everett, R. J. Glynn, J. Liu, and S. C. Kim. 2018. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: Population based cohort study. BMJ 360:k119.
Pew Charitable Trusts. 2018. Mobile fact sheet. http://www.pewinternet.org/fact-sheet/mobile (accessed December 21, 2018).
Physicians Foundation. 2018. 2018 Survey of America’s Physicians Practice Patterns and Perspectives. https://physiciansfoundation.org/wp-content/uploads/2018/09/physicianssurvey-results-final-2018.pdf (accessed December 21, 2018).
Rubin, D. and N. Thomas. 2000. Combining propensity score matching with additional adjustments for prognostic covariates. Journal of the American Statistical Association 95(450):573-585.
Ruff, C. T., R. P. Giugliano, E. Braunwald, E. B. Hoffman, N. Deenadayalu, M. D. Ezekowitz, A. J. Camm, J. I. Weitz, B. S. Lewis, A. Parkhomenko, and T. Yamashita. 2014. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. The Lancet 383(9921):955-962.
Schneeweiss, S., J. D. Seeger, J. Landon, and A. M. Walker. 2008. Aprotinin during coronary-artery bypass grafting and risk of death. New England Journal of Medicine 358(8):771-783.
Seeger, J. D., K. Bykov, D. B. Bartels, K. Huybrechts, K. Zint, and S. Schneeweiss. 2015. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thrombosis and Haemostasis 114(06):1277-1289.
Sentinel. 2018. Sentinel common data model. https://www.sentinelinitiative.org/sentinel/data/distributed-database-common-data-model/sentinel-common-data-model (accessed December 17, 2018).
Sherman, R. E., S. A. Anderson, G. J. Dal Pan, G. W. Gray, T. Gross, N. L. Hunter, L. LaVange, D. Marinac-Dabic, P. W. Marks, M. A. Robb, and J. Shuren. 2016. Real-world evidence—what is it and what can it tell us. New England Journal of Medicine 375(23):2293-2297.
Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson, and K. Fukuda. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2):179-186.
Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, C. B. Bridges, N. J. Cox, and K. Fukuda. 2004. Influenza-associated hospitalizations in the United States. JAMA 292(11):1333-1340.
Tseng, H. F., N. Smith, R. Harpaz, S. R. Bialek, L. S. Sy, and S. J. Jacobsen. 2011. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 305(2):160-166.
Udell, J. A., R. Zawi, D. L. Bhatt, M. Keshtkar-Jahromi, F. Gaughran, A. Phrommintikul, A. Ciszewski, H. Vakili, E. B. Hoffman, M. E. Farkouh, and C. P. Cannon. 2013. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: A meta-analysis. JAMA 310(16):1711-1720.
Van Ermen, A., M. P. Hermanson, J. M. Moran, N. K. Sweitzer, M. R. Johnson, and O. Vardeny. 2013. Double dose vs. standard dose influenza vaccination in patients with heart failure: A pilot study. European Journal of Heart Failure 15(5):560-564.
Vardeny, O., N. K. Sweitzer, M. A. Detry, J. M. Moran, M. R. Johnson, and M. S. Hayney. 2009. Decreased immune responses to influenza vaccination in patients with heart failure. Journal of Cardiac Failure 15(4):368-373.
Waldo, A. L., R. C. Becker, V. F. Tapson, K. J. Colgan, and NABOR Steering Committee. 2005. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. Journal of the American College of Cardiology 46(9):1729-1736.
Yih, W. K., T. A. Lieu, M. Kulldorff, D. Martin, C. N. McMahill-Walraven, R. Platt, N. Selvam, M. Selvan, G. M. Lee, and M. Nguyen. 2014. Intussusception risk after rotavirus vaccination in U.S. infants. New England Journal of Medicine 370:503-512.
Zinman, B., C. Wanner, J. M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O. E. Johansen, H. J. Woerle, and U. C. Broedl. 2015. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine 373(22):2117-2128.